Cheng-lung Hsu
Taoyuan, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.
Journal: EJNMMI research
Published: April 28, 2026
Corrigendum to "Androgen receptor may promote tumor progression via TTF-1/EGFR pathway in metastatic nasopharyngeal carcinoma" [Translational Oncology, Volume 65, March 2026, 102670].
Journal: Translational oncology
Published: April 18, 2026
SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.
Journal: American journal of cancer research
Published: December 25, 2025
Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.
Journal: EJNMMI research
Published: November 09, 2025
Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.
Journal: EJNMMI research
Published: November 09, 2025
Androgen receptor may promote tumor progression via TTF-1/EGFR pathway in metastatic nasopharyngeal carcinoma.
Journal: Translational oncology
Published: August 23, 2025
Auditory Preservation in Nasopharyngeal Carcinoma: Comparison of Proton and Photon Radiotherapy.
Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Published: July 24, 2025
SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance.
Journal: Cell death & disease
Published: April 02, 2025
Postradiotherapy Response Assessment Using 18 F-FDG PET/CT in Salivary Gland Carcinoma-A Multicenter Study.
Journal: Clinical nuclear medicine
Published: October 31, 2024
Characterization of the immune cell profile in metastatic nasopharyngeal carcinoma treated with chemotherapy and immune checkpoint inhibitors.
Journal: American journal of cancer research
Published: October 29, 2024
The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions.
Journal: Neoplasia (New York, N.Y.)
Published: July 03, 2024
Last Updated: 09/26/2026